Results 271 to 280 of about 218,137 (295)

The Prognostic Role of Programmed Death‐Ligand 1 in Nasopharyngeal Carcinoma

The Laryngoscope, 2020
ObjectivesProgrammed death‐ligand 1 (PD‐L1) is an immune checkpoint protein that may be a useful prognostic biomarker in nasopharyngeal cancer (NPC). The purpose of this systematic review and meta‐analysis was to investigate the relationship between PD‐L1 expression and survival in NPC.MethodsPubMed, Cochrane, Embase, Scopus, and Web of Science were ...
Michael Wotman, Saori W. Herman, Peter Costantino, Tristan Tham   +3 more
openaire   +2 more sources

Programmed Cell Death–Ligand 1 Overexpression in Thyroid Cancer

Endocrine Practice, 2019
Programmed cell death-ligand 1 (PD-L1) expression on tumor tissue has been associated with favorable response to anti-programmed cell death-receptor 1/PD-L1 therapy in many human cancers. Studies have reported that PD-L1 is also expressed in thyroid cancer.
Guo-Qiang, Zhang, Wei-Jun, Wei, Hong-Jun, Song, Zhen-Kui, Sun, Chen-Tian, Shen, Xin-Yun, Zhang, Xiao-Yue, Chen, Zhong-Ling, Qiu, Quan-Yong, Luo   +8 more
openaire   +2 more sources

Prognostic significance of programmed death-1 and programmed death ligand-1 proteins in breast cancer

Human Antibodies, 2022
In numerous studies related to tumor prognosis, programmed death-ligand 1 (PD-L1) has been identified as a biomarker. This work aimed to determine the prognostic importance of PD-L1 in breast cancer. We searched electronic databases such as PubMed, Google scholar, home pages of publishing groups, medical, clinical, and pharmaceutical sciences journals,
Imtiaz Mahmood, Tahir, Abdur, Rauf, Huma, Mehboob, Samia, Sadaf, Muhammad Shaiful, Alam, Fadia, Kalsoom, Abdelhakim, Bouyahya, Aicha, El Allam, Nasreddine, El Omari, Saad, Bakrim, Muhammad, Akram, Syed Kashif, Raza, Talha Bin, Emran, Yahia N, Mabkhot, Gokhan, Zengin, Marina, Derkho, Suray, Natalya, Mohammad Ali, Shariati   +17 more
openaire   +2 more sources

Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors

Expert Opinion on Biological Therapy, 2021
Introduction: In the past few years, administrating monoclonal humanized antibodies, namely checkpoint inhibitors, against programmed cell death protein 1 (PD-1), and its ligand (PD-L1), has yielded reassuring tumor regression rates. Anti-PD-1/PD-L1 checkpoint inhibitors disrupt the engagement of PD-1 on T-cells and their ligands on tumor or other ...
Parmida Sadat Pezeshki, Pouya Mahdavi Sharif, Nima Rezaei   +2 more
openaire   +2 more sources

Programmed death-ligand 1 expression in pheochromocytoma

European Urology Supplements, 2017
H. Yasuhiro, T. Tanaka, A. Imai, S. Hatakeyama, T. Yoneyama, T. Koie, C. Ohyama   +6 more
openaire   +1 more source

Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC

Journal of Thoracic Oncology, 2021
Masayuki Shirasawa, Hidehito Horinouchi, Takashi Kohno   +2 more
exaly  

Prognostic significance of programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in uterine carcinosarcoma

European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020
Ümran Kucukgoz Gulec, Emine Kilic Bagir, Semra Paydaş   +2 more
exaly  

Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis

Archives of Oral Biology, 2020
Hongzhi Quan, Liangjuan Fang
exaly  

Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer

Chest, 2017
Mónica Khunger, Adrian V Hernández, Peter J Mazzone   +2 more
exaly  

Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression

European Journal of Cancer, 2018
A Bernard-Tessier, Antoine Hollebecque, Rastilav Bahleda   +2 more
exaly